July 14th 2025
FDA approval based on FINEARTS-HF trial showing 16% risk reduction in CV death and HF events.
Semaglutide Cuts Cardiovascular Risk by 20% in Adults with Obesity, CVD and Without Diabetes
November 13th 2023AHA 2023: Semaglutide 2.4 mg reduced the risk of serious cardiovascular events by 20% in patients with obesity and overweight with established CVD but without diabetes, according to full SELECT trialresults.